The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1068
Temozolomide for Refractory Anaplastic Astrocytoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Temozolomide for Refractory Anaplastic Astrocytoma
Temozolomide has received accelerated approval from the FDA for oral treatment of adults with anaplastic astrocytoma that has relapsed after treatment with a nitrosourea (lomustine or carmustine) and procarbazine.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Temozolomide for Refractory Anaplastic Astrocytoma
Article code: 1068c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.